Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of 2 vs 3 Doses of 9vHPV Vaccine in HIV+ vs HIV- Youth in Eswatini
NCT04982614Phase 4Completed
- Sponsor
- Columbia University
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Columbia University. Primary endpoints: Anti-HPV Geometric Mean Antibody Titer (IgG) at 7 months and Number of Seroconversions at 7 months. Started Mar 2022; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04982614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982614.